Global Health Repurposing Awards 2017 Blog Series

July 13, 2017

By Jennifer Ball

Lieven GHRAWhen the weight loss drug fenfluramine, half of the “fen-phen” combination, was taken off the market, it meant the worst for families with children who have the rare epileptic disorder Dravet syndrome. Some of these children had been taking fenfluramine to treat their condition for several years. Now, parents no longer had a solution for reducing their children's seizures. Enter Dr. Lieven Lagae, Director of the Childhood Epilepsy Program at the KUL University Hospitals in Leuven, Belgium.

Recognizing that fenfluramine helped children with Dravet syndrome in his hospital's residential epilepsy center, he decided to fight to bring this treatment back to market. “Fenfluramine made a real difference in the lives of our patients with Dravet syndrome,” Dr. Lagae said. “Freedom from seizures is really not a typical progression of Dravet syndrome.”

Cures Within Reach, a nonprofit that supports repurposing drugs, devices and nutraceuticals to treat unsolved diseases, has awarded Dr. Lagae with the Cures Within Reach Industry Patient Impact Clinical Award. Read the full post!

Comments (0)

500 characters remaining

Cancel or

Sign up for our eNewsletter today!

 

First Name




Cures Within Reach

info@cureswithinreach.org

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes.  CWR is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.

 

Wednesday the 23rd. Copyright 2018 Cures Within Reach.